Documentos relacionados

1. ALSUntangled #71: Nuedexta.
2. Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
3. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.
4. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
5. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
6. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.
7. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.
8. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
9. Dextromethorphan/quinidine: in pseudobulbar affect.
10. Amyotrophic lateral sclerosis: translating genetic discoveries into therapies.